Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 10/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908760 | 0.97 | S1PR2 (0.67) | S1PR2POLBATMCYP1A2CYP3A4 | |
| SCHEMBL23915668 | 0.92 | S1PR2 (0.66) | S1PR2POLBATMMAPTTP53 | |
| SCHEMBL23908866 | 0.89 | S1PR2 (0.68) | S1PR2POLBATMMAPTTP53 | |
| SCHEMBL23909034 | 0.87 | S1PR2 (0.81) | S1PR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23966890 | 0.83 | S1PR2 (0.62) | S1PR2POLBATMCYP1A2CYP3A4 | |
| SCHEMBL23915576 | 0.81 | S1PR2 (0.67) | S1PR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23915665 | 0.81 | S1PR2 (0.62) | S1PR2POLBTP53 | |
| SCHEMBL23908889 | 0.81 | S1PR2 (0.93) | S1PR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23914820 | 0.79 | S1PR2 (0.94) | S1PR2CMA1 | |
| SCHEMBL23908951 | 0.79 | S1PR2 (1.00) | S1PR2CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885POLB 3606/4885ATM 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.